Levosimendan in septic cardiac failure

Noto, Andrea; Giacomini, Matteo; Palandi, A; Stabile, Loren; Reali-Forster, Chiara; Iapichino, G.

doi:10.1007/s00134-004-2502-3

Cited by 33 publications

(22 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Twenty-five studies were reviewed in complete form. Major exclusions were due to lack of mortality data (n = 2) [42,43] or of a randomized design (n = 14) [44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59]. Finally, seven articles (246 participants) were included in the meta-analysis [30-36] ( Table 1).…”

Section: Literature Searchmentioning

confidence: 99%

Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials

Zangrillo¹,

Putzu²,

Monaco³

et al. 2015

Journal of Critical Care

View full text Add to dashboard Cite

Section: Literature Searchmentioning

confidence: 99%

Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials

Zangrillo¹,

Putzu²,

Monaco³

et al. 2015

Journal of Critical Care

View full text Add to dashboard Cite

“…Eine Ca 2+ -Desensibilisierung wird auch als eine Komponente der septischen Kardiomyopathie postuliert [58]. Oldner et al konnten im Tierversuch zeigen, dass es durch Gabe von Levosimendan zu einem Anstieg des DO 2 in den Geweben und des portalvenösen Blutflusses kommt [59].…”

Section: Tab 4 Experimentelle Und Klinische Studien Zu Levosimendan unclassified

Role of Levosimendan in intensive care treatment of myocardial insufficiency

Rehberg¹,

Ertmer²,

Aken³

et al. 2007

Anaesthesist

View full text Add to dashboard Cite

Levosimendan is a calcium sensitizer that is currently in the focus of intensive care medicine because it may be superior to standard inotropic agents in the treatment of acute myocardial insufficiency. The effects of levosimendan mainly depend on three predominant mechanisms: 1) positive inotropic effect by increasing the sensitivity of cardiac myofilaments to calcium ions, 2) vasodilatory effect by stimulation of adenosine triphosphate-sensitive potassium channels and 3) inhibition of phosphodiesterase-III. In a large number of experimental and clinical studies further possible indications for levosimendan have been described, e.g. cardioprotection during ischemia, cardiogenic shock, septic myocardial insufficiency and pulmonary hypertension. This review article critically summarizes the current scientific and clinical knowledge about levosimendan, its pharmacologic characteristics, mechanisms of action as well as indications and potential risks.

show abstract

“…Tachyarrhythmias and increases in the energetic consumption of the myocardium are potential side effects induced by increased intracellular calcium concentration associated with the use of dobutamine and phosphodiesterase inhibitors [3]. Levosimendan has been used for the treatment of cardiac failure in different scenarios [2][3][4][5]. While levosimendan is currently widely employed in the treatment of decompensated heart failure, to the best of our knowledge, there is no report of the use of levosimendan in the treatment of acute decompensation of anthracycline-induced cardiotoxicity.…”

Section: Discussionmentioning

confidence: 94%